| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 24052 |
| Drug | Lecanemab |
| Brand | Leqembi® |
| Indication | Lecanemab (Leqembi®) is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology. |
| Assessment Process | |
| Rapid review commissioned | 19/12/2024 |
| Rapid review completed | 28/01/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lecanemab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/05/2025 |
| Pre-submission consultation with Applicant | 02/07/2025 |
| Full submission received from Applicant | 13/01/2026 |
| Preliminary review sent to Applicant | 10/04/2026 |
| NCPE assessment re-commenced | 08/06/2026 |
| Follow-up to preliminary review sent to Applicant | 29/06/2026 |
| NCPE assessment re-commenced | 20/07/2026 |
| Factual accuracy sent to Applicant | 04/09/2026 |
| NCPE assessment re-commenced | 11/09/2026 |
| NCPE assessment completed | 13/10/2026 |
| NCPE assessment outcome | The NCPE recommends that lecanemab for the treatment of adult patients, with a clinical diagnosis of Early Alzheimer’s disease (mild cognitive impairment or mild dementia due to Alzheimer’s disease), who are APOE ε4 non-carriers or heterozygotes with confirmed amyloid pathology, not be considered for reimbursement. |
The assessment was paused on 11 May 2026 at the request of the Applicant.
*Next steps: The NCPE Assessment Report and recommendation and Patient Organisation submission, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health Pricing and Supply of Medical Goods Act 2013.
Further information on this process may be found here.
Please see the HSE Pricing and Reimbursement Tracker for any updates on the reimbursement status of this drug.
HSE Pricing and Reimbursement Tracker